These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 35128745)

  • 1. Diabetes: Risk factor and translational therapeutic implications for Alzheimer's disease.
    Cummings J; Ortiz A; Castellino J; Kinney J
    Eur J Neurosci; 2022 Nov; 56(9):5727-5757. PubMed ID: 35128745
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
    Schernthaner G; Schernthaner-Reiter MH; Schernthaner GH
    Clin Ther; 2016 Jun; 38(6):1288-1298. PubMed ID: 27210264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus.
    Hemmingsen B; Sonne DP; Metzendorf MI; Richter B
    Cochrane Database Syst Rev; 2017 May; 5(5):CD012204. PubMed ID: 28489279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diabetes drugs in the fight against Alzheimer's disease.
    Boccardi V; Murasecco I; Mecocci P
    Ageing Res Rev; 2019 Sep; 54():100936. PubMed ID: 31330313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Glucagon-like peptide-1 (GLP-1) mimetics: a new treatment for Alzheimer's disease?].
    García-Casares N; García-Arnés JA; Gómez-Huelgas R; Valdivielso-Felices P; García-Arias C; González-Santos P
    Rev Neurol; 2014 Dec; 59(11):517-24. PubMed ID: 25418147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies.
    Thrasher J
    Am J Med; 2017 Jun; 130(6S):S4-S17. PubMed ID: 28526182
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies.
    Thrasher J
    Am J Cardiol; 2017 Jul; 120(1S):S4-S16. PubMed ID: 28606343
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular benefits and safety of non-insulin medications used in the treatment of type 2 diabetes mellitus.
    Yandrapalli S; Jolly G; Horblitt A; Sanaani A; Aronow WS
    Postgrad Med; 2017 Nov; 129(8):811-821. PubMed ID: 28749197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapy Insight: type 2 diabetes mellitus and the risk of late-onset Alzheimer's disease.
    Haan MN
    Nat Clin Pract Neurol; 2006 Mar; 2(3):159-66. PubMed ID: 16932542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New treatment approaches for Alzheimer's disease: preclinical studies and clinical trials centered on antidiabetic drugs.
    Katsenos AP; Davri AS; Simos YV; Nikas IP; Bekiari C; Paschou SA; Peschos D; Konitsiotis S; Vezyraki P; Tsamis KI
    Expert Opin Investig Drugs; 2022 Jan; 31(1):105-123. PubMed ID: 34941464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The mechanism and efficacy of GLP-1 receptor agonists in the treatment of Alzheimer's disease.
    Du H; Meng X; Yao Y; Xu J
    Front Endocrinol (Lausanne); 2022; 13():1033479. PubMed ID: 36465634
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glucagon-like peptide-1 (GLP-1) receptor agonists and neuroinflammation: Implications for neurodegenerative disease treatment.
    Kopp KO; Glotfelty EJ; Li Y; Greig NH
    Pharmacol Res; 2022 Dec; 186():106550. PubMed ID: 36372278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of antidiabetic agents on Alzheimer's disease biomarkers in experimentally induced hyperglycemic rat model by streptozocin.
    Ali SK; Ali RH
    PLoS One; 2022; 17(7):e0271138. PubMed ID: 35802659
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diabetes mellitus and Alzheimer's disease: shared pathology and treatment?
    Akter K; Lanza EA; Martin SA; Myronyuk N; Rua M; Raffa RB
    Br J Clin Pharmacol; 2011 Mar; 71(3):365-76. PubMed ID: 21284695
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Tale of Two Diseases: Exploring Mechanisms Linking Diabetes Mellitus with Alzheimer's Disease.
    Lynn J; Park M; Ogunwale C; Acquaah-Mensah GK
    J Alzheimers Dis; 2022; 85(2):485-501. PubMed ID: 34842187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comorbidity Analysis between Alzheimer's Disease and Type 2 Diabetes Mellitus (T2DM) Based on Shared Pathways and the Role of T2DM Drugs.
    Karki R; Kodamullil AT; Hofmann-Apitius M
    J Alzheimers Dis; 2017; 60(2):721-731. PubMed ID: 28922161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diabetes as a risk factor for Alzheimer's disease: insulin signalling impairment in the brain as an alternative model of Alzheimer's disease.
    Hölscher C
    Biochem Soc Trans; 2011 Aug; 39(4):891-7. PubMed ID: 21787319
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Type 2 Diabetes Mellitus Easily Develops into Alzheimer's Disease via Hyperglycemia and Insulin Resistance.
    Li T; Cao HX; Ke D
    Curr Med Sci; 2021 Dec; 41(6):1165-1171. PubMed ID: 34874485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drugs developed for treatment of diabetes show protective effects in Alzheimer's and Parkinson's diseases.
    Hölscher C
    Sheng Li Xue Bao; 2014 Oct; 66(5):497-510. PubMed ID: 25331995
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glycemic control of type 2 diabetes mellitus across stages of renal impairment: information for primary care providers.
    Tong L; Adler S
    Postgrad Med; 2018 May; 130(4):381-393. PubMed ID: 29667921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.